PMID- 34166063
OWN - NLM
STAT- MEDLINE
DCOM- 20211108
LR  - 20221207
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 31
IP  - 6
DP  - 2021 Aug
TI  - Inflammatory Markers Profile in Older Adolescents During Treatment with Selective 
      Serotonin Reuptake Inhibitors.
PG  - 439-444
LID - 10.1089/cap.2020.0140 [doi]
AB  - Objective: This study aimed to investigate the serum levels of inflammatory 
      markers in adolescents with major depressive disorder (MDD) using selective 
      serotonin reuptake inhibitors. Methods: This was an 8-month observational study, 
      involving 30 adolescents with and 38 without (control) MDD diagnosis. Demographic 
      (age and gender) and anthropometric data (weight, height, and calculated body 
      mass index [BMI] z score) were collected. Body composition was assessed with 
      whole-body DXA scan. Depressive and anxiety symptoms were assessed using the Beck 
      Depression and Anxiety Inventories (BDI-II and BAI), respectively. Serum levels 
      of interleukin (IL)-6, IL-8, IL-1beta, tumor necrosis factor, monocyte 
      chemoattractant protein-1 (MCP-1), leptin, resistin, and adiponectin were 
      measured using Bio-Plex Multiplex Immunoassays at baseline and after 8 months. 
      Results: At baseline, patients with MDD and controls did not differ in age, 
      gender, BMI z score, and fat mass index (FMI) z score. At follow-up, 58.3% 
      (21/36) of patients with MDD were in full remission. Patients with MDD had higher 
      levels of resistin at baseline (26274.16 pg/mL [16162.68-54252.72]) than controls 
      (21678.53 pg/mL [11221.17-37343.27]; p < 0.01). This difference remained 
      statistically significant after adjustment for sex, age, and FMI z score. No 
      differences in other inflammatory markers were observed between the groups. By 
      follow up, depressive and anxiety symptom severity had decreased significantly in 
      patients with MDD in parallel with a decrease in the serum levels of TNF 
      (p = 0.02), IL-8 (p < 0.01) and MCP-1 (p = 0.04). Among these markers, BDI-II 
      score was positively correlated with serum levels of MCP-1. Conclusion: These 
      results corroborate the view of involvement of peripheral inflammatory mechanisms 
      in the pathophysiology of MDD in adolescents. This trial is registered at 
      ClinicalTrials.gov: NCT02147184.
FAU - Martins, Lais Bhering
AU  - Martins LB
AUID- ORCID: 0000-0002-9814-8649
AD  - Department of Psychiatry and Behavioral Sciences, The University of Texas Health 
      Science Center at Houston, Houston, Texas, USA.
FAU - Delevati Colpo, Gabriela
AU  - Delevati Colpo G
AD  - Department of Psychiatry and Behavioral Sciences, The University of Texas Health 
      Science Center at Houston, Houston, Texas, USA.
FAU - Calarge, Chadi A
AU  - Calarge CA
AD  - Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of 
      Medicine, Houston, Texas, USA.
FAU - Teixeira, Antonio Lucio
AU  - Teixeira AL
AD  - Department of Psychiatry and Behavioral Sciences, The University of Texas Health 
      Science Center at Houston, Houston, Texas, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02147184
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210624
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-6)
RN  - 0 (Resistin)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anxiety/psychology
MH  - *Biomarkers
MH  - *Depressive Disorder, Major/blood/drug therapy
MH  - Female
MH  - Humans
MH  - *Inflammation
MH  - Interleukin-6/blood
MH  - Male
MH  - Psychiatric Status Rating Scales
MH  - Resistin
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Young Adult
PMC - PMC8403204
OTO - NOTNLM
OT  - SSRI
OT  - adolescents
OT  - cytokines
OT  - depression
OT  - inflammation
EDAT- 2021/06/25 06:00
MHDA- 2021/11/09 06:00
PMCR- 2022/08/01
CRDT- 2021/06/24 17:14
PHST- 2021/06/25 06:00 [pubmed]
PHST- 2021/11/09 06:00 [medline]
PHST- 2021/06/24 17:14 [entrez]
PHST- 2022/08/01 00:00 [pmc-release]
AID - 10.1089/cap.2020.0140 [pii]
AID - 10.1089/cap.2020.0140 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2021 Aug;31(6):439-444. doi: 
      10.1089/cap.2020.0140. Epub 2021 Jun 24.